# Gyrus Capital to acquire LivaNova heart valve business for €60M

Investment firm Gyrus Capital signed an agreement to acquire LivaNova's heart valve business for an enterprise value of €60 million, including plants in Italy and Canada.

- Type: Acquisition
- Announced: 2020-12-04
- Where: Saluggia, Italy; Vancouver, Canada, Italy
- Value: $73.0M (60.0M EUR)
- Jobs: 900
- Status: announced
- Products: sutureless aortic valve Perceval, tissue valves, mechanical valves
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [LivaNova](https://endata.com/companies/8038.md)
- [LivaNova](https://endata.com/companies/8038.md) (target)
- [Gyrus Capital](https://endata.com/companies/8039.md) (acquirer)

## Sources

- [medicaldevice-network.com](https://www.medicaldevice-network.com/news/gyrus-capital-livanova-valve/), 2020-12-04: "The LivaNova HV business is a global player in surgical heart valves with world-class products and compelling growth opportunities."
- [mddionline.com](https://www.mddionline.com/cardiovascular/medtech-in-a-minute-divestitures-and-m-a-oh-my-), 2020-12-07: "The divestiture is an attempt to bring LivaNova's focus back squarely on its neuromodulation and cardiovascular businesses."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.